Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 57

Results For "ABLE"

4861 News Found

Pfizer strengthens AI collaboration with XtalPi to accelerate drug discovery
Digitisation | July 01, 2025

Pfizer strengthens AI collaboration with XtalPi to accelerate drug discovery

The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development


Biocon Biologics expands insulin access in Malaysia
News | June 30, 2025

Biocon Biologics expands insulin access in Malaysia

Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served


Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market
Healthcare | June 30, 2025

Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market

The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028


Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France
Biopharma | June 29, 2025

Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France

Extended lab space for product development, customer demos, and training


Zambon launches intravenous formulation of Fluimucil
Drug Approval | June 29, 2025

Zambon launches intravenous formulation of Fluimucil

The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile


FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels
Drug Approval | June 28, 2025

FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access


European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME
Drug Approval | June 28, 2025

European Commission approves Eylea 8 mg with extended 6-month treatment interval for nAMD and visual impairment due to DME

Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME


Biocon Biologics receives Health Canada approval for Yesafili
Drug Approval | June 27, 2025

Biocon Biologics receives Health Canada approval for Yesafili

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data


Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation
News | June 27, 2025

Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation

Star Health Insurance is modernising its claims ecosystem to be future-ready


Philogen withdraws marketing authorization application for Nidlegy in EU
News | June 26, 2025

Philogen withdraws marketing authorization application for Nidlegy in EU

The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls